Safety of Therapeutic Step-down in Neuromyelitis Optica

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

947 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuromyelitis Optica (NMO) is a neuroinflammatory disease related to multiple sclerosis (MS). It affects young subjects and causes a lot of handicap without treatment. Thus, aggressive treatments are frequently introduced early in the life of patients and maintained over the long term. A long duration of treatment exposes to iatrogenism. Therapeutic de-escalation trials in MS or other autoimmune diseases show rebound phenomena. In the NMO, there are no published data on the tolerance of desescalations to guide such strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

NCT02200770

Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

COMPLETED PHASE2/PHASE3

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

NCT05214794

Systemic Sclerosis

COMPLETED PHASE2

Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod

NCT02277964

Relapsing Remitting Multiple Sclerosis

COMPLETED

Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients

NCT02809079

Neuromyelitis Optica Spectrum Disorders Mycophenolate Mofetil Efficacy and Safety

UNKNOWN PHASE4

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

NCT01499667

Relapsing Remitting Multiple Sclerosis (RRMS)

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromyelitis Optica

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major patients who have received long-term treatment for NMO
* Patients with a prospectively diagnosed NMO using the 2015 NMO classification criteria (IPND)
* Patients who retrospectively meet the classification criteria of the 2015 NMO (IPND)
* Patients who have not expressed their opposition, after information, to the reuse of their data for research purposes.

Exclusion Criteria

* Patient who expressed his opposition to participating in the study
* Lack of data on the assay of anti-AQP4 and anti-MOG antibodies
* Less than a year of taking a second-line treatment before the relay
* End of follow-up \<1 year following the transfer, this therefore includes patients whose transfer took place less than one year before the date of data extraction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No